Johnson & Johnson (NYSE:JNJ) Stock Price Up 1.2% – Time to Buy?

Shares of Johnson & Johnson (NYSE:JNJ) rose 1.2% on Thursday. The stock traded as high as $286.08 and last traded at $283.69. Approximately 7,697,257 shares changed hands during trading, a decline of 3% from the average daily volume of 7,955,198 shares. The stock had previously closed at $280.41.

Johnson & Johnson News Summary

These are some of the JNJ news items that stood out recently:

• Positive Sentiment: J&J also led a $100 million funding round for Delix Therapeutics, supporting development of psychedelic-inspired depression treatments. Separately, favorable Phase 3 CAPLYTA results for bipolar I mania could offer a path to broaden the drug’s use. J&J backs cancer device and leads depression investment Johnson & Johnson reports favorable data for bipolar study
• Positive Sentiment: Underlying growth prospects remain a support: oncology sales rose 16.8% to $22 billion in the first nine months of 2026, and recent launches are expected to help offset patent losses. J&J’s oncology sales surge so far in 2026
• Negative Sentiment: A Massachusetts jury awarded a family about $3.3 million in a mesothelioma case involving J&J talc-based baby powder. The company also faces a law-firm investigation into investor claims. The award is small relative to J&J’s scale, but the developments keep talc litigation and potential liabilities in focus. Massachusetts family awarded $3.3 million against Johnson & Johnson Pomerantz investigates claims on behalf of J&J investors

Wall Street Analysts Forecast Growth

Several research firms have commented on JNJ. Morgan Stanley lowered their price objective on Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating on the stock in a research report on Thursday, October 15th. UBS Group set a $270.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 14th. Raymond James Financial set a $280.00 target price on shares of Johnson & Johnson in a research note on Monday, August 3rd. HSBC increased their price target on shares of Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Finally, Freedom Capital upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $275.92.

Johnson & Johnson Stock Up 1.2%

The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. The business’s 50 day simple moving average is $266.67 and its 200 day simple moving average is $249.23. The company has a market capitalization of $682.93 billion, a PE ratio of 42.98, a P/E/G ratio of 2.78 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion during the quarter, compared to analysts’ expectations of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is presently 81.21%.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jennifer L. Taubert sold 15,000 shares of the business’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is owned by company insiders.

Institutional Investors Weigh In On Johnson & Johnson

A number of institutional investors have recently made changes to their positions in JNJ. Outlook Capital Management LLC purchased a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $28,000. Matrix Trust Co raised its position in Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after purchasing an additional 54 shares during the period. Navigoe LLC lifted its stake in Johnson & Johnson by 60.4% during the third quarter. Navigoe LLC now owns 146 shares of the company’s stock worth $38,000 after purchasing an additional 55 shares in the last quarter. Montgomery Financial Services LLC acquired a new position in Johnson & Johnson during the second quarter worth $43,000. Finally, Hanseatic Management Services Inc. purchased a new position in shares of Johnson & Johnson during the third quarter worth $52,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

About Johnson & Johnson

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.